Science

Jun 17, 2025, 09:11

Myeloma Paper of the Day, June 17th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Post-hoc analysis of VTE on BENEFIT study finds 6-mo. cumulative rate 4.8% (0.8% on low-dose DOACs, 5.6% on prophylactic heparin, 9.8% on aspirin); only 1 VTE beyond 6-month period; 1/3 patients with VTE had no prophylaxis.”

Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT

Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu

You can read the Full Article in the Journal of Thrombosis and Haemostasis.

More posts featuring Robert Orlowski.

Aurore Perrot BENEFIT Bernard Tardy cancer Corinne Frere Cyrille Hulin Elisabeth Daguenet Emilie Chalayer Laurent Frenzel Myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Salomon Manier Thierry Facon Thomas Lecompte Xavier Leleu

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More